Terapia Génica en Enfermedad de Parkinson
PARKBA SAL
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (57)
2024
-
Development and characterization of a non-human primate model of disseminated synucleinopathy
Frontiers in Neuroanatomy, Vol. 18
2023
-
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease
Parkinsonism and Related Disorders, Vol. 110
-
AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability
Brain, Behavior, and Immunity, Vol. 108, pp. 255-268
-
Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease
Neurobiology of Disease, Vol. 188
-
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates
Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014
-
Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome
Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601
2022
-
Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives
Biomedicines, Vol. 10, Núm. 4
-
Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment
Life, Vol. 12, Núm. 11
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses
International Journal of Molecular Sciences, Vol. 22, Núm. 12
-
An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria
Redox Biology, Vol. 46
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques
International Journal of Molecular Sciences, Vol. 22, Núm. 9
2020
-
Brain ventricular enlargement in human and murine acute intermittent porphyria
Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164
-
Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum
Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42
-
Neuroanatomical tract-tracing techniques that did go viral
Brain Structure and Function, Vol. 225, Núm. 4, pp. 1193-1224
2019
-
Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings
Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405
-
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine
Movement Disorders, Vol. 34, Núm. 1, pp. 9-21
-
Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Molecular Neurobiology, Vol. 56, Núm. 8, pp. 5900-5910